Pulmatrix Inc.
This article was originally published in Start Up
Executive Summary
Originally intent on developing a contagion-prevention product for biodefense, Pulmatrix Inc. now has much larger ambitions. The company believes its new technologies for formulating drugs as dry powders and delivering them via inhalers will make its lead respiratory drug candidate more convenient and potent. Pulmatrix also sees the methods as a discovery engine likely to give rise to partnerships and branded generics.
You may also be interested in...
Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.
Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.
Pearl Therapeutics Inc.
Drawing on a proprietary porous particle technology to create stable inhalable suspensions, Pearl Therapeutics Inc. has developed a metered-dose inhaler format able to deliver combination products across therapeutics and product types. The company's lead chronic obstructive pulmonary disease MDI candidate combines a long-acting muscarinic antagonist plus a long acting beta-2 agonist. A mid-stage clinical trial demonstrated significant benefits versus blockbuster, market-leading active comparators in patients with moderate-to-very severe COPD.
Need a specific report? 1000+ reports available
Buy Reports